Executive Summary

No Q1 FY2025 8‑K “Item 2.02” earnings press release or earnings call transcript was found; the most recent primary-source financials are FY2024 (year ended Aug 31, 2024) and quarterly 8‑Ks through Q3 FY2024. The company was delisted from Nasdaq on Nov 6, 2024 and now trades OTC Pink, adding uncertainty to disclosures and investor communication cadence .
FY2024 revenue rose 6% to $13.29M, but the net loss widened 22% to $16.17M, driven by impairment, FX losses, and amortization of debt discounts. Quarterlies through Q3 FY2024 show revenue in the $3.15–$3.89M range with volatile losses tied to derivative liability marks and financing costs .
Liquidity and capital structure remain key: cash was $0.84M at FY end; Streeterville’s secured note had an outstanding balance of $6.58M after an October redemption paid in shares, and the Board has authority for a reverse split (approved by shareholders, ratio TBD) to potentially facilitate future capital actions .
Catalysts into Q1 FY2025 include leadership transition (CEO resignation effective Feb 5, 2025), reverse split authorization, and continued Streeterville redemptions, all of which could influence trading dynamics, dilution risk, and investor sentiment .

What Went Well and What Went Wrong

What Went Well

Product-led topline: FY2024 revenue increased 6% YoY to $13.29M, with management emphasizing commercialization of proprietary products and a multi-pillar growth model .
Quarterly service resilience: healthcare services revenue increased YoY in successive quarters (+1.2% in Q1 FY2024, +3.4% in Q2, +8.1% in Q3), suggesting underlying demand stability despite mix shifts toward products .
Operational focus: “maximizing operational efficiencies” cited in Q2 FY2024, and management reiterated commitment to decentralizing healthcare via technology and product innovation—“remains committed to the commercialization of its proprietary product offerings” .

What Went Wrong

Exchange delisting: common stock was delisted from Nasdaq and moved to OTC Pink on Nov 6, 2024, complicating capital markets access and liquidity .
Loss drivers intensified: Q3 FY2024 net loss surged to $(13.74)M on a $6.72M derivative liability loss, $2.90M amortization of debt discount, and $1.41M FX loss—highlighting financing-related volatility and balance sheet complexity .
Tight liquidity with heavier current liabilities: FY2024 cash was $0.84M vs. current liabilities $14.58M; derivative liability at FY end was $4.69M—underscoring refinancing risk and potential dilution .

Financial Results

Note: No Q1 FY2025 8‑K 2.02 press release or call transcript was found. Below are the most recent quarterly and annual figures available.

Metric	Q1 FY2024 (Nov 30, 2023)	Q2 FY2024 (Feb 29, 2024)	Q3 FY2024 (May 31, 2024)
Revenue ($USD)	$3,891,218	$3,170,592	$3,151,851
Cost of Revenues ($USD)	$1,947,200	$1,846,506	$2,254,958
Gross Profit ($USD)	$1,944,018	$1,324,086	$896,893
Net Loss Attributed to NVOS ($USD)	$(4,680,343)	$(2,746,128)	$(13,741,903)
Diluted EPS ($USD)	$(0.28)	$(0.16)	$(0.74)
Revenue YoY Growth (%)	+14.0%	+24.0%	−4.3%

KPI	Q1 FY2024 (Nov 30, 2023)	Q2 FY2024 (Feb 29, 2024)	Q3 FY2024 (May 31, 2024)
Cash & Equivalents ($USD)	$1,640,007	$651,747	$1,539,771
Total Assets ($USD)	$37,244,384	$34,949,271	$35,327,000
Total Liabilities ($USD)	$13,960,336	$13,058,987	$25,663,779
Stockholders’ Equity ($USD)	$23,284,048	$21,890,284	$9,663,221

Segment/Contribution	Q1 FY2024	Q2 FY2024	Q3 FY2024
Acenzia Revenue ($USD)	$1,683,850	$884,396	$884,396
Terragenx Revenue ($USD)	$16,971	$103,399	$103,399
Healthcare Services Revenue YoY (%)	+1.2%	+3.4%	+8.1%

FY2024 (year ended Aug 31, 2024) snapshot:

Metric	FY2024
Revenue ($USD)	$13,294,357
Gross Profit ($USD)	$5,742,504
Operating Expenses ($USD)	$15,818,802
Net Loss Attributed to NVOS ($USD)	$(16,166,744)
Cash & Equivalents ($USD)	$844,584
Total Assets ($USD)	$32,141,276
Total Liabilities ($USD)	$17,527,351
Equity ($USD)	$14,613,925

Guidance Changes

Metric	Period	Previous Guidance	Current Guidance	Change
Revenue	Q1 FY2025	None disclosed in available documents	None disclosed in available documents	Maintained: No formal guidance
Margins	Q1 FY2025	None disclosed in available documents	None disclosed in available documents	Maintained: No formal guidance
OpEx	Q1 FY2025	None disclosed in available documents	None disclosed in available documents	Maintained: No formal guidance
Tax Rate	Q1 FY2025	None disclosed in available documents	None disclosed in available documents	Maintained: No formal guidance
Segment Revenue	Q1 FY2025	None disclosed in available documents	None disclosed in available documents	Maintained: No formal guidance
Dividends	Q1 FY2025	No cash dividends intention (10‑K)	No change indicated	Maintained

Earnings Call Themes & Trends

Note: No earnings call transcript was found for Q1 FY2025; themes below reflect press releases and filings.

Topic	Previous Mentions (Q1–Q3 FY2024)	Current Period (Q1 FY2025 context)	Trend
Financing/Capital Access	Highlighted pending non‑traditional financing; Streeterville note raised in April; emphasis on foundational capital	Streeterville monthly redemption; $142,500 redemption paid in shares; outstanding balance $6.58M	Financing ongoing; equity-linked redemptions increase dilution risk
Exchange Listing/Corporate Actions	Regained minimum bid compliance post 1:10 reverse split in Nov 2023	Delisted to OTC Pink Nov 6, 2024; shareholders approved reverse split (1:10 to 1:30)	Deteriorated listing status; optional reverse split flexibility retained
Product Commercialization	Emphasis across quarters on proprietary products (Acenzia, Terragenx)	Continued strategic focus in FY2024 PR/10‑K; no Q1 FY2025 product metrics disclosed	Narrative consistent; limited disclosure depth
Technology/Decentralization	Repeated messaging on telehealth/RPM and Novo Connect	10‑K reiterates platform commercialization plans into spring 2025	Execution staged; commercialization timeline into CY2025
Legal/Regulatory	n/a	Ophir gemstone purchase agreement terminated Oct 17, 2024	Transaction risk resolved; foregone monetization path
Leadership	n/a	CEO resignation effective Feb 5, 2025; remains Board Chair	Transition underway

Management Commentary

“The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions…” (Q1 FY2024 PR) .
“The Company’s fiscal year 2024 second quarter period emphasized maximizing operational efficiencies…” (Q2 FY2024 PR) .
“The Company’s fiscal year 2024 third quarter emphasized maximizing operational efficiencies…” (Q3 FY2024 PR) .
FY2024 PR reiterates focus on non‑dilutive capital and product/service expansion .

Q&A Highlights

No analyst Q&A available; an earnings call transcript for Q1 FY2025 was not found in the document set.

Estimates Context

Wall Street consensus (S&P Global) for Q1 FY2025 was unavailable via our estimates tool for NVOS due to missing SPGI/CIQ mapping. As a result, no consensus comparisons can be provided at this time.

Key Takeaways for Investors

Disclosure cadence risk: No Q1 FY2025 8‑K 2.02 or call transcript found; investors should anticipate irregular reporting while the company trades OTC Pink .
Financing overhang: Streeterville’s secured convertible note with active redemptions and equity payments increases dilution risk; outstanding balance post-October redemption was $6.58M .
Balance sheet constraints: FY2024 cash $0.84M vs. current liabilities $14.58M; derivative liability $4.69M—refinancing and dilution risk likely to remain central to the thesis .
Profitability path challenged: FY2024 net loss widened 22% to $16.17M; quarterly swings tied to derivative liability marks, debt discount amortization, and FX losses—a key focus for any near-term re-rating .
Corporate actions as trading catalysts: Shareholder-approved reverse split (ratio TBD) and CEO transition (effective Feb 5, 2025) could drive near-term volatility and potential structural moves to re-access capital markets .
Product/services underpinning revenue: Acenzia and Terragenx contributions plus healthcare services growth provide base revenue, but scale is modest and not yet offsetting financing-related costs .
Monitor filings: Watch for the next 8‑K 2.02 or 10‑Q to establish Q1 FY2025 actuals and any guidance—absent formal guidance to date, new disclosures will be pivotal .

Novo Integrated Sciences, Inc. (NVOS)·Q1 2025 Earnings Summary